相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Randomised phase II trial of gemcitabine plus vinorelbine vs gemcitabine plus cisplatin vs gemcitabine plus capecitabine in patients with pretreated metastatic breast cancer
H. J. Stemmler et al.
BRITISH JOURNAL OF CANCER (2011)
RIBBON-1: Randomized, Double-Blind, Placebo-Controlled, Phase III Trial of Chemotherapy With or Without Bevacizumab for First-Line Treatment of Human Epidermal Growth Factor Receptor 2-Negative, Locally Recurrent or Metastatic Breast Cancer
Nicholas J. Robert et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study
Javier Cortes et al.
LANCET (2011)
Reputation and Precedent in the Bevacizumab Decision
Daniel Carpenter et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Iniparib plus Chemotherapy in Metastatic Triple-Negative Breast Cancer.
Joyce O'Shaughnessy et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Cisplatin-gemcitabine therapy in metastatic breast cancer: Improved outcome in triple negative breast cancer patients compared to non-triple negative patients
Nebu Koshy et al.
BREAST (2010)
Efficacy of ixabepilone in ER/PR/HER2-negative (triple-negative) breast cancer
Edith A. Perez et al.
BREAST CANCER RESEARCH AND TREATMENT (2010)
Phase II study of oral vinorelbine in combination with capecitabine as second line chemotherapy in metastatic breast cancer patients previously treated with anthracyclines and taxanes
Alison Jones et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2010)
Triple-Negative Breast Cancer Role of Specific Chemotherapy Agents
Steven J. Isakoff
CANCER JOURNAL (2010)
Pathologic Complete Response Rates in Young Women With BRCA1-Positive Breast Cancers After Neoadjuvant Chemotherapy
Tomasz Byrski et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Rechallenging with anthracyclines and taxanes in metastatic breast cancer
Carlo Palmieri et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2010)
Triple-Negative Breast Cancer
William D. Foulkes et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Cyclophosphamide Dose Intensification May Circumvent Anthracycline Resistance of p53 Mutant Breast Cancers
Jacqueline Lehmann-Che et al.
ONCOLOGIST (2010)
Molecular Stratification of Triple-Negative Breast Cancers
Charles M. Perou
ONCOLOGIST (2010)
Third consensus on medical treatment of metastatic breast cancer
S. Beslija et al.
ANNALS OF ONCOLOGY (2009)
Epidermal growth factor receptor as a potential therapeutic target in triple-negative breast cancer
B. Corkery et al.
ANNALS OF ONCOLOGY (2009)
Pattern of metastatic spread in triple-negative breast cancer
Rebecca Dent et al.
BREAST CANCER RESEARCH AND TREATMENT (2009)
Survival Outcomes for Patients with Metastatic Triple-Negative Breast Cancer: Implications for Clinical Practice and Trial Design
Farrah Kassam et al.
CLINICAL BREAST CANCER (2009)
Molecular Characterization of Breast Cancer with High-Resolution Oligonucleotide Comparative Genomic Hybridization Array
Fabrice Andre et al.
CLINICAL CANCER RESEARCH (2009)
Triple-Negative Breast Cancer: Distinguishing between Basal and Nonbasal Subtypes
Emad A. Rakha et al.
CLINICAL CANCER RESEARCH (2009)
High-dose chemotherapy for high-risk primary and metastatic breast cancer: is another look warranted?
Yago Nieto et al.
CURRENT OPINION IN ONCOLOGY (2009)
The clinical efficacy of cytotoxic agents in locally advanced or metastatic breast cancer patients pretreated with an anthracycline and a taxane: A systematic review
Jacek Jassem et al.
EUROPEAN JOURNAL OF CANCER (2009)
Treatment outcomes and clinicopathologic characteristics of triple-negative breast cancer patients who received platinum-containing chemotherapy
Ji Eun Uhm et al.
INTERNATIONAL JOURNAL OF CANCER (2009)
Gastrosplenic Fistula From Hodgkin's Lymphoma
Carolyn D. Seib et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Cost Effectiveness of Ixabepilone Plus Capecitabine for Metastatic Breast Cancer Progressing After Anthracycline and Taxane Treatment
Shelby D. Reed et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Pegylated Liposomal Doxorubicin Plus Docetaxel Significantly Improves Time to Progression Without Additive Cardiotoxicity Compared With Docetaxel Monotherapy in Patients With Advanced Breast Cancer Previously Treated With Neoadjuvant-Adjuvant Anthracycline Therapy: Results From a Randomized Phase III Study
Joseph A. Sparano et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
International Guidelines for Management of Metastatic Breast Cancer: Combination vs Sequential Single-Agent Chemotherapy
Fatima Cardoso et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2009)
Basal-like breast cancer defined by five biomarkers has superior prognostic value then triple-negative phenotype
Maggie C. U. Cheang et al.
CLINICAL CANCER RESEARCH (2008)
Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100
Bryan P. Schneider et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane
Harold J. Burstein et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer
Cornelia Liedtke et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Clinical Development of Ixabepilone and Other Epothilones in Patients with Advanced Solid Tumors
Edgardo Rivera et al.
ONCOLOGIST (2008)
Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer
Kathy Miller et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment
Eva S. Thomas et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in patients with taxane-resistant metastatic breast cancer
Eva Thomas et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Triple-negative breast cancer: Clinical features and patterns of recurrence
Rebecca Dent et al.
CLINICAL CANCER RESEARCH (2007)
Investigation of tumor biomarkers as response predictors in a monotherapy study with lapatinib (L) as a first line treatment in ErbB2 amplified women with breast cancer
H. L. Gomez et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
The p63/p73 network mediates chemosensitivity to cisplatin in a biologically defined subset of primary breast cancers
Chee-Onn Leong et al.
JOURNAL OF CLINICAL INVESTIGATION (2007)
The triple negative paradox: Primary tumor chemosensitivity of breast cancer subtypes
Lisa A. Carey et al.
CLINICAL CANCER RESEARCH (2007)
Biomarkers and multiple drug resistance in breast cancer
L. O'Driscoll et al.
CURRENT CANCER DRUG TARGETS (2006)
Molecular mechanisms of drug resistance
DB Longley et al.
JOURNAL OF PATHOLOGY (2005)
Facts and controversies in systemic treatment of metastatic breast cancer
C Bernard-Marty et al.
ONCOLOGIST (2004)
Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: Phase III trial results
J O'Shaughnessy et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
分享论文
